Most show a smaller measured effect than exercise or the prescription options
Semaglutide carries a boxed warning for risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), and is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Iron Minerals play several key roles in energy production
Unlock your body's full potential with our premium Vitamin B12 supplement
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
Read more OVERVIEW SPECIFICATIONS DOCUMENTS Benzamidine Sepharose 4 Fast Flow (High Sub) is an excellent tool for removal of proteolytic activity from a protein Benzamidine Sepharose 4 Fast Flow (high sub) is based on highly cross-linked 4% agarose enabling high flow rates without losing binding capacity p-aminobenzamidine (pABA) immobilized on Sepharose 4 Fast Flow matrix gives high productivity, and allows easy scale-up
